KEVIN PARK

Allopathic & Osteopathic Physicians|Internal Medicine PEARLAND, TX NPI 1548840705

General Payments — all program years on this page

$541.51

  • Category: General Payments
  • Program years: PY2022–2024
  • Record count: 27
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $426.74 across 21 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $426.7421

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2022 $56.793
2023 $57.983
2024 $426.7421

Records — PY2024 (21)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096822913 Novo Nordisk Inc $13.67 10/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096882335 Novo Nordisk Inc $19.80 08/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096895291 Novo Nordisk Inc $17.78 09/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096902453 Novo Nordisk Inc $30.82 12/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097033076 Novo Nordisk Inc $22.36 11/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097658472 Novo Nordisk Inc $20.63 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097761935 Novo Nordisk Inc $21.22 09/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097803463 Novo Nordisk Inc $25.02 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104299350 AstraZeneca Pharmaceuticals LP $25.44 08/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104352102 AstraZeneca Pharmaceuticals LP $14.11 10/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104485632 AstraZeneca Pharmaceuticals LP $18.38 09/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104551198 AstraZeneca Pharmaceuticals LP $16.15 11/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105201318 AstraZeneca Pharmaceuticals LP $21.40 10/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105507558 AstraZeneca Pharmaceuticals LP $17.06 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114823050 Exact Sciences Corporation $23.34 10/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125121715 Abbott Laboratories $23.53 10/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135128474 Lilly USA, LLC $17.06 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139331646 Astellas Pharma US Inc $24.07 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139365637 Astellas Pharma US Inc $20.70 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141571488 Merck Sharp & Dohme LLC $18.89 09/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147899560 Supernus Pharmaceuticals, Inc. $15.31 05/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.